Last reviewed · How we verify

Quinapril + Losartan

AHEPA University Hospital · FDA-approved active Small molecule

This combination blocks two different pathways in the renin-angiotensin-aldosterone system (RAAS) to lower blood pressure: quinapril inhibits ACE while losartan blocks angiotensin II receptors.

This combination blocks two different pathways in the renin-angiotensin-aldosterone system (RAAS) to lower blood pressure: quinapril inhibits ACE while losartan blocks angiotensin II receptors. Used for Hypertension, Heart failure.

At a glance

Generic nameQuinapril + Losartan
SponsorAHEPA University Hospital
Drug classACE inhibitor + Angiotensin II receptor blocker combination
TargetAngiotensin-converting enzyme (ACE) and Angiotensin II type 1 receptor (AT1R)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Quinapril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, while losartan is an angiotensin II receptor blocker (ARB) that directly blocks AT1 receptors. Together, they provide dual RAAS inhibition through complementary mechanisms, resulting in enhanced vasodilation, reduced aldosterone secretion, and greater blood pressure reduction than either agent alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results